Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma

BACKGROUND: Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials. Talimogene laherparepvec (T-VEC) is the first oncolyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Schvartsman, Gustavo, Perez, Kristen, Flynn, Jill E., Myers, Jeffrey N., Tawbi, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477138/
https://www.ncbi.nlm.nih.gov/pubmed/28642816
http://dx.doi.org/10.1186/s40425-017-0250-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477138/
https://www.ncbi.nlm.nih.gov/pubmed/28642816
http://dx.doi.org/10.1186/s40425-017-0250-5

Ejemplares similares